Western Financial Corp CA Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Western Financial Corp CA trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 870 shares of the biopharmaceutical company’s stock after selling 833 shares during the period. Western Financial Corp CA’s holdings in Regeneron Pharmaceuticals were worth $620,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at $37,000. Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on REGN. Citigroup cut their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $672.98 on Friday. The company’s 50-day moving average is $720.81 and its two-hundred day moving average is $924.07. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $73.95 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.